NCT00006097

Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

CC-1088 Therapy for Chronic Lymphocytic Leukemia: A Phase I/II Trial

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Boston Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CC-1088 in treating patients who have chronic lymphocytic leukemia that has not responded to previous therapy.

Detailed description

OBJECTIVES: I. Determine the toxicity of CC-1088 in patients with refractory, progressive, B-cell chronic lymphocytic leukemia. II. Determine the response rate to this treatment in these patients. OUTLINE: Patients receive oral CC-1088 three times a day for 28 days. Treatment continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 11-20 patients will be accrued for this study.

Conditions

• Leukemia

Interventions

Type	Name	Description
DRUG	CC-1088

Timeline

• Start date: 1999-08-01
• Primary completion: 2005-07-01
• Completion: 2005-07-01
• First posted: 2004-05-04
• Last updated: 2010-09-22

Locations

1 site across 1 country: United States